1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Biosimilars Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Biosimilars Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Rising demand for biosimilars due to cost-effectiveness
- 5.1.2 Expanding use of biosimilars in oncology and immunology
5.2 Market Opportunities
- 5.2.1 Adoption of biosimilars to lower healthcare costs
- 5.2.2 Expansion into emerging markets with biosimilar drugs
5.3 Future Trends
- 5.3.1 Growing adoption of biosimilars
- 5.3.2 Support for biosimilar approvals
5.4 Impact of Drivers and Restraints
6. North America Biosimilars Market Regional Analysis
6.1 North America Biosimilars Market Overview
6.2 North America Biosimilars Market Revenue 2020-2028 (US$ Million)
6.3 North America Biosimilars Market Forecast Analysis
7. North America Biosimilars Market Analysis – by Disease Indication
7.1 Cancer
- 7.1.1 Overview
- 7.1.2 Cancer: North America Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Diabetes
- 7.2.1 Overview
- 7.2.2 Diabetes: North America Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Autoimmune Diseases
- 7.3.1 Overview
- 7.3.2 Autoimmune Diseases: North America Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Other Diseases
- 7.4.1 Overview
- 7.4.2 Other Diseases: North America Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Biosimilars Market Analysis – by Drug Class
8.1 Granulocyte Colony-Stimulating Factors
- 8.1.1 Overview
- 8.1.2 Granulocyte Colony-Stimulating Factors: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Human Growth Hormone
- 8.2.1 Overview
- 8.2.2 Human Growth Hormone: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Insulin
- 8.3.1 Overview
- 8.3.2 Insulin: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 TNF Blockers & Monoclonal Antibodies
- 8.4.1 Overview
- 8.4.2 TNF Blockers & Monoclonal Antibodies: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Erythropoietin-Stimulating Agents
- 8.5.1 Overview
- 8.5.2 Erythropoietin-Stimulating Agents: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Biosimilars Market Analysis – by Route of Administration
9.1 Intravenous
- 9.1.1 Overview
- 9.1.2 Erythropoietin-Stimulating Agents: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Subcutaneous
- 9.2.1 Overview
- 9.2.2 Erythropoietin-Stimulating Agents: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Biosimilars Market – North America Analysis
10.1 North America
- 10.1.1 North America Biosimilars Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 10.1.1.1 North America Biosimilars Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 US:
North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.1.1 US: North America Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.1.2 US: North America Biosimilars Market Breakdown, by Drug Class
- 10.1.1.1.3 US: North America Biosimilars Market Breakdown, by Route of Administration
- 10.1.1.2 Canada:
North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.2.1 Canada: North America Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.2.2 Canada: North America Biosimilars Market Breakdown, by Drug Class
- 10.1.1.2.3 Canada: North America Biosimilars Market Breakdown, by Route of Administration
- 10.1.1.3 Mexico :
North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.3.1 Mexico : North America Biosimilars Market Breakdown, by Disease Indication
- 10.1.1.3.2 Mexico : North America Biosimilars Market Breakdown, by Drug Class
- 10.1.1.3.3 Mexico : North America Biosimilars Market Breakdown, by Route of Administration
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. North America Biosimilars Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Amgen Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Celltrion Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Sanofi SA
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Biocon Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Coherus BioSciences Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Eli Lilly and Co
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Sandoz AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Teva Pharmaceutical Industries Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Pfizer Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Dr. Reddy's Laboratories Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For North America Biosimilars Market
